Abstract:Plasticity is an inherent feature of cancer stem cells (CSCs) and regulates the balance of key processes required at different stages of breast cancer progression, including epithelial-to-mesenchymal transition (EMT) versus mesenchymal-to-epithelial transition (MET), and glycolysis versus oxidative phosphorylation. Understanding the key factors that regulate the switch between these processes could lead to novel therapeutic strategies that limit tumor progression. We found that aldehyde dehydrogenase 1A3 (ALDH1A3) regulates these cancer-promoting processes and the abundance of the two distinct breast CSC populations defined by high ALDH activity and CD24 − CD44 + cell surface expression. While ALDH1A3 increases ALDH + breast cancer cells, it inversely suppresses the CD24 − CD44 + population by retinoic acid signaling-mediated gene expression changes. This switch in CSC populations induced by ALDH1A3 was paired with decreased migration but increased invasion and an intermediate EMT phenotype. We also demonstrate that ALDH1A3 increases oxidative phosphorylation and decreases glycolysis and reactive oxygen species (ROS). The effects of ALDH1A3 reduction were countered with the glycolysis inhibitor 2-deoxy-D-glucose (2DG). In cell culture and tumor xenograft models, 2DG suppresses the increase in the CD24 − CD44 + population and ROS induced by ALDH1A3 knockdown. Combined inhibition of ALDH1A3 and glycolysis best reduces breast tumor growth and tumor-initiating cells, suggesting that the combination of targeting ALDH1A3 and glycolysis has therapeutic potential for limiting CSCs and tumor progression. Together, these findings identify ALDH1A3 as a key regulator of processes required for breast cancer progression and depletion of ALDH1A3 makes breast cancer cells more susceptible to glycolysis inhibition.

Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.

Aldehyde Dehydrogenase 3A1 is Robustly Upregulated in Gastric Cancer Stem-Like Cells and Associated with Tumorigenesis.

Aldehyde Dehydrogenases and Cancer Stem Cells.

High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer.

Aldehyde Dehydrogenase 1 in Gastric Cancer

ALDHHigh Breast Cancer Stem Cells Exhibit a Mesenchymal–Senescent Hybrid Phenotype, with Elevated Metabolic and Migratory Activities

Aldehyde dehydrogenase 1 is a tumor stem cell-Associated marker in lung cancer

The Prognostic Roles of Aldh1 Isoenzymes in Gastric Cancer

ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.

ALDH1A1 Maintains the Cancer Stem-Like Cells Properties of Esophageal Squamous Cell Carcinoma by Activating the AKT Signal Pathway and Interacting with Β-Catenin.

High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling

Targeting Aldehyde Dehydrogenases to Eliminate Cancer Stem Cells in Gynecologic Malignancies

Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: identification of prognostic microenvironmental factors after chemoradiation

Aldh Maintains The Stemness Of Lung Adenoma Stem Cells By Suppressing The Notch/Cdk2/Ccne Pathway

Cancer Stem Cell Marker ALDH1 Expression is Associated with Lymph Node Metastasis and Poor Survival in Esophageal Squamous Cell Carcinoma: a Study from High Incidence Area of Northern China.

Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.

Salinomycin can effectively kill ALDHhigh stem-like cells on gastric cancer

ALDH1A3 is the switch that determines the balance of ALDH + and CD24 − CD44 + cancer stem cells, EMT-MET, and glucose metabolism in breast cancer

Molecular profiling of ALDH1+ colorectal cancer stem cells reveals preferential activation of MAPK, FAK, and oxidative stress pro-survival signalling pathways

ALDH and cancer stem cells: Pathways, challenges, and future directions in targeted therapy

Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers